Severe eyelid oedema in Graves’ ophthalmopathy

We report a case of severe eyelid oedema due to Graves’ ophthalmopathy (GO). The aim was to present a case report and review of the literature about eyelid oedema due to GO. The case report includes a history of patient data and literature review. The patient was offered intravenous methylprednisolo...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2013-07, Vol.2013, p.bcr2013010305
Main Authors: Anagnostis, Panagiotis, Adamidou, Fotini, Poulasouchidou, Maria, Karras, Spyridon
Format: Article
Language:English
Subjects:
Edema - drug therapy
Edema - etiology
Europe (West)
Eyelid Diseases - drug therapy
Eyelid Diseases - etiology
Female
Glucocorticoids - therapeutic use
Graves Ophthalmopathy - complications
Graves Ophthalmopathy - drug therapy
Humans
Methylprednisolone - therapeutic use
Middle Aged
Radiation therapy
Severity of Illness Index
Thyroid gland
Unusual Presentation of More Common Disease/Injury
White
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b5775-5a2f5452ab5589ad01547000de5444eac48f009b9f69df28da605ee4b093e7953
cites cdi_FETCH-LOGICAL-b5775-5a2f5452ab5589ad01547000de5444eac48f009b9f69df28da605ee4b093e7953
container_end_page
container_issue
container_start_page bcr2013010305
container_title BMJ case reports
container_volume 2013
creator Anagnostis, Panagiotis
Adamidou, Fotini
Poulasouchidou, Maria
Karras, Spyridon
description We report a case of severe eyelid oedema due to Graves’ ophthalmopathy (GO). The aim was to present a case report and review of the literature about eyelid oedema due to GO. The case report includes a history of patient data and literature review. The patient was offered intravenous methylprednisolone and gave consent. A dosage of 500 mg intravenous methylprednisolone once weekly for 6 weeks, followed by 250 mg intravenous methylprednisolone once weekly for 6 weeks, with a total treatment period of 12 weeks was given. Up to day, minor improvement has been observed. Severe eyelid oedema due to GO is a rare manifestation of Graves’ disease. In cases of active and moderate-to-severe disease, treatment with intravenous glucorticoids is recommended alone or with orbital radiotherapy, followed by rehabilitative surgery.
doi_str_mv 10.1136/bcr-2013-010305
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3736300</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4030597531</sourcerecordid><originalsourceid>FETCH-LOGICAL-b5775-5a2f5452ab5589ad01547000de5444eac48f009b9f69df28da605ee4b093e7953</originalsourceid><addsrcrecordid>eNqFkEFLwzAYhoMobsydvUnBm1CXNEnTXAQZOoWBBxW8hbT9ajvapqbdoDf_hn_PX2JG55gnc0kgT97vzYPQOcHXhNBwFifWDzChPiaYYn6ExkRw4QuJ344PziM0bdsVdosSFjF6ikYBjTglko4RfoYNWPCgh7JIPQMpVNoram9h9Qba788vzzR5l-uyMo3u8v4MnWS6bGG62yfo9f7uZf7gL58Wj_PbpR9zIbjPdZBxxgMdcx5JnWLCmXAVUuCMMdAJizKMZSyzUKZZEKU6xByAxVhSEJLTCboZcpt1XEGaQN1ZXarGFpW2vTK6UH9v6iJX72ajqKAhdX-doMtdgDUfa2g7tTJrW7vOioiIBhF2pKNmA5VY07YWsv0EgtXWsnKW1dayGiy7FxeHxfb8r1MHXA1AXK3-TfsBIHCFOQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1783280373</pqid></control><display><type>article</type><title>Severe eyelid oedema in Graves’ ophthalmopathy</title><source>NCBI_PubMed Central（免费）</source><creator>Anagnostis, Panagiotis ; Adamidou, Fotini ; Poulasouchidou, Maria ; Karras, Spyridon</creator><creatorcontrib>Anagnostis, Panagiotis ; Adamidou, Fotini ; Poulasouchidou, Maria ; Karras, Spyridon</creatorcontrib><description>We report a case of severe eyelid oedema due to Graves’ ophthalmopathy (GO). The aim was to present a case report and review of the literature about eyelid oedema due to GO. The case report includes a history of patient data and literature review. The patient was offered intravenous methylprednisolone and gave consent. A dosage of 500 mg intravenous methylprednisolone once weekly for 6 weeks, followed by 250 mg intravenous methylprednisolone once weekly for 6 weeks, with a total treatment period of 12 weeks was given. Up to day, minor improvement has been observed. Severe eyelid oedema due to GO is a rare manifestation of Graves’ disease. In cases of active and moderate-to-severe disease, treatment with intravenous glucorticoids is recommended alone or with orbital radiotherapy, followed by rehabilitative surgery.</description><identifier>ISSN: 1757-790X</identifier><identifier>EISSN: 1757-790X</identifier><identifier>DOI: 10.1136/bcr-2013-010305</identifier><identifier>PMID: 23853193</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Edema - drug therapy ; Edema - etiology ; Europe (West) ; Eyelid Diseases - drug therapy ; Eyelid Diseases - etiology ; Female ; Glucocorticoids - therapeutic use ; Graves Ophthalmopathy - complications ; Graves Ophthalmopathy - drug therapy ; Humans ; Methylprednisolone - therapeutic use ; Middle Aged ; Radiation therapy ; Severity of Illness Index ; Thyroid gland ; Unusual Presentation of More Common Disease/Injury ; White</subject><ispartof>BMJ case reports, 2013-07, Vol.2013, p.bcr2013010305</ispartof><rights>2013 BMJ Publishing Group Ltd</rights><rights>Copyright: 2013 2013 BMJ Publishing Group Ltd</rights><rights>2013 BMJ Publishing Group Ltd 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b5775-5a2f5452ab5589ad01547000de5444eac48f009b9f69df28da605ee4b093e7953</citedby><cites>FETCH-LOGICAL-b5775-5a2f5452ab5589ad01547000de5444eac48f009b9f69df28da605ee4b093e7953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736300/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736300/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23853193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anagnostis, Panagiotis</creatorcontrib><creatorcontrib>Adamidou, Fotini</creatorcontrib><creatorcontrib>Poulasouchidou, Maria</creatorcontrib><creatorcontrib>Karras, Spyridon</creatorcontrib><title>Severe eyelid oedema in Graves’ ophthalmopathy</title><title>BMJ case reports</title><addtitle>BMJ Case Rep</addtitle><description>We report a case of severe eyelid oedema due to Graves’ ophthalmopathy (GO). The aim was to present a case report and review of the literature about eyelid oedema due to GO. The case report includes a history of patient data and literature review. The patient was offered intravenous methylprednisolone and gave consent. A dosage of 500 mg intravenous methylprednisolone once weekly for 6 weeks, followed by 250 mg intravenous methylprednisolone once weekly for 6 weeks, with a total treatment period of 12 weeks was given. Up to day, minor improvement has been observed. Severe eyelid oedema due to GO is a rare manifestation of Graves’ disease. In cases of active and moderate-to-severe disease, treatment with intravenous glucorticoids is recommended alone or with orbital radiotherapy, followed by rehabilitative surgery.</description><subject>Edema - drug therapy</subject><subject>Edema - etiology</subject><subject>Europe (West)</subject><subject>Eyelid Diseases - drug therapy</subject><subject>Eyelid Diseases - etiology</subject><subject>Female</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Graves Ophthalmopathy - complications</subject><subject>Graves Ophthalmopathy - drug therapy</subject><subject>Humans</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Middle Aged</subject><subject>Radiation therapy</subject><subject>Severity of Illness Index</subject><subject>Thyroid gland</subject><subject>Unusual Presentation of More Common Disease/Injury</subject><subject>White</subject><issn>1757-790X</issn><issn>1757-790X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkEFLwzAYhoMobsydvUnBm1CXNEnTXAQZOoWBBxW8hbT9ajvapqbdoDf_hn_PX2JG55gnc0kgT97vzYPQOcHXhNBwFifWDzChPiaYYn6ExkRw4QuJ344PziM0bdsVdosSFjF6ikYBjTglko4RfoYNWPCgh7JIPQMpVNoram9h9Qba788vzzR5l-uyMo3u8v4MnWS6bGG62yfo9f7uZf7gL58Wj_PbpR9zIbjPdZBxxgMdcx5JnWLCmXAVUuCMMdAJizKMZSyzUKZZEKU6xByAxVhSEJLTCboZcpt1XEGaQN1ZXarGFpW2vTK6UH9v6iJX72ajqKAhdX-doMtdgDUfa2g7tTJrW7vOioiIBhF2pKNmA5VY07YWsv0EgtXWsnKW1dayGiy7FxeHxfb8r1MHXA1AXK3-TfsBIHCFOQ</recordid><startdate>20130713</startdate><enddate>20130713</enddate><creator>Anagnostis, Panagiotis</creator><creator>Adamidou, Fotini</creator><creator>Poulasouchidou, Maria</creator><creator>Karras, Spyridon</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20130713</creationdate><title>Severe eyelid oedema in Graves’ ophthalmopathy</title><author>Anagnostis, Panagiotis ; Adamidou, Fotini ; Poulasouchidou, Maria ; Karras, Spyridon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b5775-5a2f5452ab5589ad01547000de5444eac48f009b9f69df28da605ee4b093e7953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Edema - drug therapy</topic><topic>Edema - etiology</topic><topic>Europe (West)</topic><topic>Eyelid Diseases - drug therapy</topic><topic>Eyelid Diseases - etiology</topic><topic>Female</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Graves Ophthalmopathy - complications</topic><topic>Graves Ophthalmopathy - drug therapy</topic><topic>Humans</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Middle Aged</topic><topic>Radiation therapy</topic><topic>Severity of Illness Index</topic><topic>Thyroid gland</topic><topic>Unusual Presentation of More Common Disease/Injury</topic><topic>White</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anagnostis, Panagiotis</creatorcontrib><creatorcontrib>Adamidou, Fotini</creatorcontrib><creatorcontrib>Poulasouchidou, Maria</creatorcontrib><creatorcontrib>Karras, Spyridon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anagnostis, Panagiotis</au><au>Adamidou, Fotini</au><au>Poulasouchidou, Maria</au><au>Karras, Spyridon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe eyelid oedema in Graves’ ophthalmopathy</atitle><jtitle>BMJ case reports</jtitle><addtitle>BMJ Case Rep</addtitle><date>2013-07-13</date><risdate>2013</risdate><volume>2013</volume><spage>bcr2013010305</spage><pages>bcr2013010305-</pages><issn>1757-790X</issn><eissn>1757-790X</eissn><abstract>We report a case of severe eyelid oedema due to Graves’ ophthalmopathy (GO). The aim was to present a case report and review of the literature about eyelid oedema due to GO. The case report includes a history of patient data and literature review. The patient was offered intravenous methylprednisolone and gave consent. A dosage of 500 mg intravenous methylprednisolone once weekly for 6 weeks, followed by 250 mg intravenous methylprednisolone once weekly for 6 weeks, with a total treatment period of 12 weeks was given. Up to day, minor improvement has been observed. Severe eyelid oedema due to GO is a rare manifestation of Graves’ disease. In cases of active and moderate-to-severe disease, treatment with intravenous glucorticoids is recommended alone or with orbital radiotherapy, followed by rehabilitative surgery.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>23853193</pmid><doi>10.1136/bcr-2013-010305</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1757-790X
ispartof BMJ case reports, 2013-07, Vol.2013, p.bcr2013010305
issn 1757-790X
1757-790X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3736300
source NCBI_PubMed Central（免费）
subjects Edema - drug therapy
Edema - etiology
Europe (West)
Eyelid Diseases - drug therapy
Eyelid Diseases - etiology
Female
Glucocorticoids - therapeutic use
Graves Ophthalmopathy - complications
Graves Ophthalmopathy - drug therapy
Humans
Methylprednisolone - therapeutic use
Middle Aged
Radiation therapy
Severity of Illness Index
Thyroid gland
Unusual Presentation of More Common Disease/Injury
White
title Severe eyelid oedema in Graves’ ophthalmopathy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T10%3A53%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20eyelid%20oedema%20in%20Graves%E2%80%99%20ophthalmopathy&rft.jtitle=BMJ%20case%20reports&rft.au=Anagnostis,%20Panagiotis&rft.date=2013-07-13&rft.volume=2013&rft.spage=bcr2013010305&rft.pages=bcr2013010305-&rft.issn=1757-790X&rft.eissn=1757-790X&rft_id=info:doi/10.1136/bcr-2013-010305&rft_dat=%3Cproquest_pubme%3E4030597531%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b5775-5a2f5452ab5589ad01547000de5444eac48f009b9f69df28da605ee4b093e7953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1783280373&rft_id=info:pmid/23853193&rfr_iscdi=true